Adaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho Securities

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAPResearch Report), with a price target of $9.00. The company’s shares opened today at $2.42.

Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Adaptimmune Therapeutics, and Merck & Company. According to TipRanks, Goldstein has an average return of 0.6% and a 36.02% success rate on recommended stocks.

Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.25.

See Insiders’ Hot Stocks on TipRanks >>

ADAP market cap is currently $385M and has a P/E ratio of -2.15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Read More on ADAP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More